Patient Monitoring Stocks Q3 Recap: Benchmarking Masimo (NASDAQ:MASI)
Shareholders should contact the firm immediately as there may be limited time to enforce your rights. Â
Masimo (MASI) Stock Is Up, What You Need To Know
Announces Long-Range Targets Including 7% - 10% Revenue CAGR Through 2028 Highlights Clear Focus on Patient Outcomes, Technology Innovation and Commercial Execution
1 Volatile Stock to Target This Week and 2 We Ignore
Clover Health, GoodRx, Moderna, UFP Technologies, and Masimo Shares Are Soaring, What You Need To Know
IRVINE, Calif. , Nov. 18, 2025 /PRNewswire/ -- A team from Knobbe Martens led medical device pioneer Masimo (NASDAQ: MASI) to a victory over Apple in a dispute involving Masimo's patented heart monitoring...
2 Small-Cap Stocks to Target This Week and 1 That Underwhelm
Masimo (NASDAQ: MASI) today issued the following statement in response to the jury verdict announced in the U.S. District Court for the Central District of California, which confirmed the validity...
5 Insightful Analyst Questions From Masimo’s Q3 Earnings Call